https://cvvr.hms.harvard.edu/publication/nl-preliminary-aggregate-safety-and-immunogenicity-results-from-three-trials-of-a-purified-inactivated-zika-virus-vaccine-candidate-phase-1-randomised-double-blind-placebo-controlled-clinical-tri/
NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.